GLP-1s Around Pregnancy Show No Clear Risks, Studies Find

The use of GLP-1 receptor agonists (GLP-1 RAs) around the time of pregnancy has not demonstrated a clear increase in adverse maternal or perinatal outcomes, according to findings from two recent studies. A systematic review and meta-analysis, encompassing 10 studies and over 2.1 million pregnancies, examined the safety profile of these widely used medications. The analysis specifically looked at outcomes such as major congenital malformations, spontaneous abortions, stillbirths, and preterm births. While the aggregate data did not reveal statistically significant increases in these adverse events, researchers emphasized the need for continued vigilance and further investigation.

GLP-1 RAs, including popular medications like semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Victoza, Saxenda), are primarily prescribed for type 2 diabetes management and weight loss. Their efficacy in these areas has led to widespread adoption, prompting increased interest in their use across broader patient populations, including those who are pregnant or planning to become pregnant. Historically, many medications have been contraindicated or used with extreme caution during pregnancy due to potential risks to the developing fetus. However, the current evidence suggests that for GLP-1 RAs, the risks may be lower than previously assumed, or at least not definitively established as higher than baseline risks.

Despite the reassuring findings, both studies strongly advocate for a cautious approach. The authors highlighted that the existing data, while extensive, may still have limitations. These can include variations in study designs, differences in how GLP-1 RAs were used (e.g., timing and duration of exposure relative to conception and pregnancy), and potential confounding factors that were not fully controlled for. Furthermore, the studies noted that the long-term developmental outcomes for children exposed to GLP-1 RAs in utero have not been extensively studied. Therefore, healthcare providers are advised to carefully weigh the benefits and risks for individual patients, considering alternative treatment options where appropriate, and to maintain close monitoring throughout pregnancy.

The research underscores a growing body of evidence that challenges earlier assumptions about the risks associated with certain medications during pregnancy. As the understanding of GLP-1 RAs evolves, ongoing research and post-market surveillance will be crucial in refining clinical guidelines and ensuring the safest possible care for pregnant individuals and their offspring. The findings are expected to inform discussions between patients and clinicians regarding the management of conditions like diabetes and obesity in the context of pregnancy, potentially leading to more nuanced treatment strategies.